Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases.
The last earnings update was 46 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Adverum Biotechnologies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Adverum Biotechnologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
Adverum Biotechnologies is not considered high growth as it is expected to be loss making for the next 1-3 years.
Adverum Biotechnologies's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Adverum Biotechnologies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Adverum Biotechnologies's finances.
The net worth of a company is the difference between its assets and liabilities.
Adverum Biotechnologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Adverum Biotechnologies's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Adverum Biotechnologies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 1043.8x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Leone D. Patterson serves as the Chief Executive Officer and Director of Adverum Biotechnologies, Inc. since October 12, 2018. Ms. Patterson has been the Chief Financial Officer at Adverum Biotechnologies, Inc. since June 15, 2016 and served as Senior Vice President since February 2018 until May 3, 2018. She served as the President of Adverum Biotechnologies, Inc. since October 12, 2018 until November 2018. She served as the Interim President and Chief Executive Officer of Adverum Biotechnologies, Inc. since May 3, 2018 until October 12, 2018. Ms. Patterson has more than 20 years of Finance and Accounting experience. Ms. Patterson served as the Chief Financial Officer of Diadexus, Inc. from March 16, 2015 to June 10, 2016. Ms. Patterson served as the Chief Financial Officer and Vice President of Transcept Pharmaceuticals, Inc. from June 25, 2012 to October 30, 2014. Ms. Patterson served as Chief Financial Officer and Vice President of Paratek Pharmaceuticals, Inc. until October 30, 2014. She served as Principal Accounting Officer at Transcept Pharmaceuticals, Inc. From November 2010 to June 2012, she served as a Vice President and Corporate Controller at Net App. From November 2010 to June 2012, Ms. Patterson served as Vice President and Global Corporate Controller of NetApp, Inc. From July 2007 to November 2010, she served as Vice President of Finance at Exelixis. Ms. Patterson served as Vice President of Global Business Planning Analysis of the Vaccines and Diagnostics Division at Novartis AG from April 2006 to July 2007, where she oversaw the business planning and analysis function for the Vaccines and Diagnostics Division. From 1999 to 2006, She held several positions at Chiron, Corp., including as its Vice President since November 2003 and Corporate Controller since 2001. Ms. Patterson joined Chiron Corporation in 1999 as Director of Special Projects in the corporate finance group. Ms. Patterson worked at KPMG LLP as a Senior Manager in the San Francisco audit practice for two years. She served at KPMG LLP from 1989 to 1999. She served with KPMG Auckland in the New Zealand audit practice for eight years. Ms. Patterson was a Certified Public Accountant. Ms. Patterson received a B.S. degree in Business Administration and Accounting from Chapman University and an Executive M.B.A. and graduated with honors from St. Mary's College. Ms. Patterson is also a Certified Public Accountant (inactive status).
Insufficient data for Leone to compare compensation growth.
Insufficient data for Leone to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Adverum Biotechnologies management team is less than 2 years, this suggests a new team.
President & Chief Scientific Officer
Co-Founder & Director
CEO, CFO & Director
VP, General Counsel & Corporate Secretary
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Adverum Biotechnologies board of directors is less than 3 years, this suggests a new board.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.